Recent Articles from GlobeNewswire

ROCHESTER, NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Syntec Optics (Nasdaq: OPTX), a leading producer of mission-critical space optics, today announced nearly a 2x year-over-year increase in commercial satellite laser optics production volume shipping in 2026 over 2025. 

As market conditions allow, facility provides access to incremental capital to support XRP acquisitions, product development in the XRP ecosystem and general corporate purposes

Proposed transaction of an estimated $15 million supports WISeSat.Space’s commercial development and establishes initial satellite, mission control and ground infrastructure for the Quantum Spatial Orbital Cloud

Holders choose the price at which they tender; offer provides an optional path to liquidity, and holders who do not tender retain all existing rights

Limited-edition Shadow Green FUGA DU 2 Trail Shoe Released

RADNOR, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2026 before market open on Thursday, November 5th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET.

Phase 1 plant now in stable operation following commissioning; first liquid helium in storage ahead of initial deliveries to contracted offtakers

Recognition highlights Optery’s approach to helping prevent phishing and other social engineering attacks by removing the exposed personal data attackers use to target employees and executives

SOL treasury reaches 2,595,612 as Solana enters a new era of near-instant transaction finality

PALM BEACH, Florida, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Gabelli is hosting the 8th Annual Healthcare Symposium in conjunction with Columbia Business School on Friday, November 13, 2026, at the Paley Center in New York. The symposium brings together leading companies and organizations from across the healthcare ecosystem, with an emphasis on industry dynamics, current trends, and business fundamentals.

BOSTON, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL a leading provider of technology-enabled care, will report third quarter 2026 operating results after stock market trading hours on Tuesday, November 3.

Companies to combine OPT’s PowerBuoy® platforms and patent portfolio with Stratum’s GPU infrastructure to advance edge AI inference powered by wave, wind, and solar energy

First clinical evaluation of investigational, transmitter-free one-year CGM marks an important milestone on Senseonics’ innovation roadmap, with potential launch in 2028

Larger resource base strengthens potential to extend mine life

TORONTO, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Timbercreek Financial (TSX: TF) will release financial results for the quarter ended September 30, 2026 on Wednesday, November 11, 2026 after market close. The Company will host a live conference call and webcast on Thursday, November 12, 2026 to discuss results with analysts and investors.

CAMBRIDGE, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Novastra Therapeutics, a clinical-stage biotechnology company developing a novel category of cancer immune therapy, reported encouraging initial data from an ongoing investigator-initiated Phase 1 study representing the first clinical evidence for its systematic immune reprogramming therapy (XIRT™) based on its proprietary OmniAntigen™ Platform (OAP). The data were presented on Saturday, October 24, at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.

~ First Earnings Call as a U.S.-Domiciled, Nasdaq-Listed Company; Results to Be Reported Under U.S. GAAP ~

SAN DIEGO, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS), a Technology Company in the Defense, National Security and Global Markets, announced today that it will publish financial results for the third quarter 2026 after the close of market on Thursday, November 5th. Management will discuss the Company’s operations and financial results in a conference call beginning at 2:00 p.m. Pacific (5:00 p.m. Eastern).

Portage, Michigan, Oct. 26, 2026 (GLOBE NEWSWIRE) --

67% of U.S. respondents say AI adoption is outpacing workforce preparation, while 68% across six countries say organizations are losing important skills or expertise without realizing it

Powered by 443,000+ FOREWARN users and 660+ REALTOR® associations and MLSs throughout the U.S., the new capability enables agents to instantly warn one another about concerning interactions

RESTON, Va., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Comscore, Inc. (Nasdaq: SCOR), a trusted partner for planning, transacting and evaluating media, today announced that it plans to hold a conference call to discuss its financial results for the third quarter ended September 30, 2026 on Tuesday November 3rd at 5:00 p.m. ET.

X1 automates travel, alignment, hammering and plumb in a single command, letting one operator do the work of a two-person crew

SAN FRANCISCO, Oct. 26, 2026 (GLOBE NEWSWIRE) -- BrainHQ brain training is now being used by SWAT teams, police departments, sheriff’s offices and other first responders across the world to help thousands of public safety personnel make faster and better split-second decisions. The National Tactical Officers Association (NTOA) began offering brain training four years ago. At this year’s annual gathering of SWAT teams, the NTOA presented BrainHQ with the Spirit of NTOA Award — given annually to an individual or organization for “outstanding partnership, visionary leadership, and an enduring commitment to enhancing officer performance, and saving lives.”

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) --

Vancouver, British Columbia, Oct. 26, 2026 (GLOBE NEWSWIRE) -- NevGold Corp. (“NevGold” or the “Company”) (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50) is pleased to announce the appointment of Mr. Sean I. Waller., M.Sc. Eng., FCIM, to its Board of Directors, effective immediately. Mr. Waller adds key project development experience to the NevGold Board of Directors at a time when the Company is entering the Engineering Phase.

VANCOUVER, BRITISH COLUMBIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- HI-VIEW RESOURCES INC. (“Hi-View” or the “Company”) (CSE: GXLD; OTCQB: GXLDF; FSE: B630) announces preliminary results from its 2026 exploration program at the Black Pearl target, part of its 100%-owned property in the Toodoggone District of north-central British Columbia (the “Property”).Preliminary results from the induced polarization (“IP”) survey, supported by geological mapping and field observations, have identified compelling exploration targets consistent with the potential for a concealed porphyry system at depth. Geological observations suggest a possible vertical transition from higher-elevation, shallower low- to intermediate-sulphidation (“LS–IS”) epithermal alteration and mineralization at the Har showing to deeper-level pyrite-rich stringers that cut an intermediate to felsic dyke recently discovered near the Gord Davies West showing in the valley bottom.

Recertification caps a year in which founder and CEO Juhi Saha was named to Inc.’s 2026 Female Founders 500 and Partner1 was named an Inc. Power Partner for the second year running

Maranello (Italy), October 26, 2026 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) informs that the Company has purchased, under the Euro 250 million share buyback program announced on September 1, 2026, as the third tranche of the multi-year share buyback program of approximately Euro 3.5 billion expected to be executed by 2030 in line with the disclosure made during the 2025 Capital Markets Day (the “Third Tranche”), the additional common shares - reported in aggregate form, on a daily basis - on the Euronext Milan (EXM) as follows:

Acquisition adds battery-free smart wound dressing and two-minute multi-marker screening test to Davion’s growing healthcare portfolio

Nasdaq closes the minimum bid price matter confirming that the Company has regained compliance

- Ongoing Pivotal Phase 3 trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel versus standard-of-care chemotherapy in first-line metastatic pancreatic cancer -

XTX501 is a novel PD-1/masked IL-2 bispecific that has the potential to become a foundational backbone regimen for solid tumors

WILMINGTON, DELAWARE, Oct. 26, 2026 (GLOBE NEWSWIRE) -- CID HoldCo, Inc., doing business as Dot Ai (Nasdaq: DAIC) (“Dot Ai” or the “Company”), today announced the appointment of Avi Cohen to its Board of Directors. Cohen brings extensive experience leading technology companies through acquisitions, integration and expansion as Dot Ai enters its next phase of growth following the recent $65 million acquisition of its wholly owned subsidiary, Envoy Technologies.

ROCKVILLE, MD, Oct. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced positive interim data from its ongoing Phase 2 LINNET study evaluating lorigerlimab, a bispecific DART® molecule that targets PD-1 and CTLA-4, in patients with CCGC. These Phase 2 data were presented today at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain. 

Third Quarter Highlights

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Serapha Bio, Inc. (Serapha), a clinical-stage genetic medicines company committed to transforming the treatment of alpha-1 antitrypsin deficiency (AATD), today announced early clinical data for YOLT-202 (SERP-01), an investigational one-time in vivo base editing therapy, from the ongoing investigator-initiated trial (IIT) evaluating its safety and efficacy in four participants with the PiZZ genotype. Simon Krooss, M.D., Ph.D. of Hannover Medical School presented the data at the European Respiratory Society Alpha-1 Antitrypsin Conference 2026, held on October 23-24 in Barcelona, Spain. The IIT is being conducted through a collaboration between Renji Hospital in Shanghai, China and Hannover Medical School in Germany.

RICHMOND, Va., Oct. 26, 2026 (GLOBE NEWSWIRE) -- ARKO Corp. (Nasdaq: ARKO) (the “Company”), a Fortune 1000 company and one of the largest convenience store operators and wholesalers of fuel in the United States, today announced that the Company will host a conference call on Thursday, November 5, 2026 at 9:00 a.m. Eastern Time to discuss its financial results for the third quarter ended September 30, 2026.

NEWTON, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results for the third quarter of 2026 and provided a business update.

Transformation Efforts Continue to Drive Growth and Profitability 

Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom occurrence

Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense, adding value of approximately $270 million

Aoxiangyu 819, Aoyu 966, and Aoyu 288 delivered yield gains of 6.0% to 8.6% over control varieties in two-year national regional trials; 30-day public notice period runs through November 22, 2026

Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated patients

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third quarter 2026 financial results and provide a business update on Monday, November 2, 2026.

50% Confirmed Objective Response Rate (ORR) with All Responses Ongoing in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026

Active LN patients in the Phase 1 study treated with FT819 and the less-intensive conditioning (bendamustine) regimen selected for the RECLAIM-LN study achieved 100% renal response at Month 6, with approximately 50% mean reduction in proteinuria

SAN DIEGO, Oct. 26, 2026 (GLOBE NEWSWIRE) -- VETmAb Biosciences (VETmAb BIO), a clinical-stage biopharmaceutical company developing transformative biologics for pets, today announced positive clinical proof-of-concept results for VMB-C001a. VMB-C001a is a long-acting anti-IL-23 monoclonal antibody for canine chronic inflammatory enteropathy (CIE), often referred to as inflammatory bowel disease (IBD). VMB-C001a has been granted eligibility for the FDA-CVM’s expanded conditional approval (XCA) pathway.

MONTREAL, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Gildan Activewear Inc. (“Gildan” or the “Company”) today announced it has completed the previously announced sale of HanesBrands Australia (“HAA”) to BBFIT Investments Pte Ltd, an associated entity of BB Retail Capital, a global private investment firm, for approximately $700 million Australian dollars (approximately $490 million US dollars), paid in cash at closing. HAA has been classified as held for sale and reported as discontinued operations in Gildan’s financial statements since the fourth quarter of 2025. Gildan intends to use the net proceeds from the transaction to repay outstanding debt.

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Centauri Minerals Inc. (TSX-V: CENT; OTCQX: CNTIF), a mineral exploration company, has qualified to trade on the OTCQX® Best Market. Centauri Minerals Inc. upgraded to OTCQX from the Pink Limited™ Market.

FORT WORTH, Texas, Oct. 26, 2026 (GLOBE NEWSWIRE) -- HighPeak Energy, Inc. (NASDAQ: HPK) (“HighPeak Energy”), today announced that it plans to release its 2026 third quarter financial and operating results after the close of trading on Monday, November 9, 2026.

Digit humanoid robots to expand to additional GXO sites in 2027, building on industry-first Robots-as-a-Service agreement

RICHMOND, Va., Oct. 26, 2026 (GLOBE NEWSWIRE) -- ARKO Petroleum Corp. (Nasdaq: APC) (“APC” or the “Company”), one of the largest wholesale fuel distributors by gallons in North America, today announced that the Company will host a conference call on Wednesday, November 4, 2026 at 5:00 p.m. Eastern Time to discuss its financial results for the third quarter ended September 30, 2026.

61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A

MADRID and BOSTON, Oct. 26, 2026 (GLOBE NEWSWIRE) -- BPGbio, Inc., a clinical-stage biopharmaceutical company advancing mitochondrial-targeted therapeutics for patients, today announced encouraging updated results from its Phase 2 clinical trial evaluating BPM31510, an investigational mitochondrial modulator, in combination with standard-of-care radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed glioblastoma multiforme (GBM) patients. The findings were presented on October 24th at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

Proceeds intended to support the proposed acquisition and planned conversion of a computing center in Youngstown, Ohio

NASA and USGS will compare EarthDaily Constellation data with Landsat observations and evaluate its potential to support AI-ready products and future hybrid government-commercial mission architectures

BEIJING, Oct. 26, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced its third quarter 2026 results and business highlights for the nine-months ended September 30, 2026.

New facility expands industrial seal repair, service, and training capacity following investments in Peru and China.

BERKELEY HEIGHTS, N.J. and WESTFIELD, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Corxel Pharmaceuticals, Inc. (“Corxel US”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for obesity and related cardiometabolic conditions, and Amanat Acquisition Corp (Nasdaq: AMAN) (“Amanat”), a publicly traded special purpose acquisition company, today announced they have entered into a definitive business combination agreement.

SAN FRANCISCO, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Girard Sharp LLP, a national investment, securities, and consumer class action firm, is investigating potential securities claims on behalf of former Liberty Broadband Corporation (“Liberty Broadband”) investors who received shares of Charter Communications, Inc. (“Charter” or the “Company”) in connection with Charter’s acquisition of Liberty Broadband on August 20, 2026 (“Merger”).

MILLBRAE, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the presentation of updated data for EIK1001 at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain.

SAN FRANCISCO, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP, Girard Sharp LLP, and The Hall Firm, Ltd., all national law firms specializing in complex class actions and shareholder rights, announce they have filed a class action lawsuit for violations of the federal securities laws against Compass, Inc. (“Compass” or “Company”) (NYSE: COMP) and certain officers and directors of Compass and Anywhere Real Estate Inc. (“Anywhere”). The class action asserts claims under Sections 11, 12(a)(2), and 15 of the Securities Act of 1933 on behalf of former Anywhere shareholders who acquired newly issued Compass common stock in direct exchange for their Anywhere securities in the January 9, 2026 stock-for-stock transaction (the “Merger”) by which Compass merged with and acquired Anywhere (the “Class”). The case is pending in the United States District Court for the Southern District of New York and is captioned: Magloire v. Compass, Inc., et al., No. 1:26-cv-08885 (S.D.N.Y.).

Aviatrix Makes Clearance Free to Every Enterprise Through May 1, 2027, So Security Teams Have Time to Patch with a Containment Backstop in Place

MAINZ, Germany and SHANGHAI, China, October 26, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and DualityBiologics (Suzhou) Co., Ltd. (“DualityBio”, HKEX: 9606.HK) announced today that the DYNASTY-Breast02 global Phase 3 clinical trial (NCT06018337) met its primary endpoint demonstrating a statistically significant, yet modest improvement in progression-free survival (“PFS”) with trastuzumab pamirtecan (BNT323/DB-1303) compared to investigator’s choice of chemotherapy in chemotherapy-naïve patients with HR+/HER2-low metastatic breast cancer who have progressed on endocrine therapy. At this interim analysis for the secondary endpoint of overall survival (“OS”), data were not mature.

SINGAPORE, Oct. 26, 2026 (GLOBE NEWSWIRE) -- EngageLab, an AI-first customer engagement platform, today announced its partnership with CoinW, one of the world's leading cryptocurrency trading platforms. Founded in 2017, CoinW provides a one-stop, intelligent trading experience for users worldwide. CoinW is integrating EngageLab’s AppPush, OTP, and Email capabilities into its transaction messaging infrastructure to support secure and reliable communications for its global user base.

— ORPATHYS® plus TAGRISSO® reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting — 

FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced the U.S. Food and Drug Administration’s (FDA’s) establishment of a public docket (Docket No. FDA-2026-N-13038) to solicit comment on legal and regulatory questions regarding certain issues raised by a filer of an abbreviated new drug application (ANDA) referencing VOQUEZNA® (vonoprazan) tablets, BDR Pharmaceuticals, International Pvt. Ltd. (BDR), in litigation brought against the FDA following FDA’s rejection of the ANDA. The litigation was brought to challenge FDA’s June 6, 2025 decision granting Phathom’s Citizen Petition, which agreed with Phathom that VOQUEZNA benefits from 10 years of New Chemical Entity (NCE) exclusivity through May 3, 2032. The deadline for comments submitted to the public docket is November 23, 2026.

Former CEO of BNY’s European Bank brings decades of experience across financial services, regulation and strategic transformation

STMicroelectronics introduces first automotive safety combination sensors for mass-market applications

Hydro is pleased to invite investors, analysts, financial media and other stakeholders to its Investor Day on November 25, 2026.

The Singapore-registered EBC Group Foundation, funded entirely by EBC Financial Group, sets one condition for every project it supports and aims to help at least 6,000 people by the end of 2027

Harbin Institute of Technology (HIT)